ImmunityBio (IBRX) said Thursday that US Urology Partners has begun administering its recombinant Bacillus Calmette-Guerin, or rBCG, in the US as part of an effort to address a shortage of Tice BCG.
The company said the shortage of Tice BCG is a "significant impediment" to treating bladder cancer.
ImmunityBio said the US Food and Drug Administration recently authorized ImmunityBio's Expanded Access Program for rBCG, and 60 urology centers are preparing to launch the treatment.
The company said it is working with the Serum Institute of India to produce rBCG.
Price: 2.84, Change: -0.03, Percent Change: -1.05
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。